RCT: Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma.
17 Mar, 2022 | 08:07h | UTC
Commentary on Twitter
Phase III JUPITER-03 trial testing addition of the anti-PD-1 mAb toripalimab to first-line chemotherapy for advanced-stage ESCC, mPFS was 5.7 vs 5.5 months, although 1-year PFS was 27.8% vs 6.1% (HR 0.58) and mOS was 17 vs 11 months (HR 0.58): https://t.co/jNSVzNiAzR #esocsm
— NatureRevClinOncol (@NatRevClinOncol) March 10, 2022